MedVital has raised ₹18 crore in a growth funding round led by Alkemi Growth Capital, with participation from Dr. Sanjay Arora, Shubhan Ventures and existing investors. The development follows the company’s previous round led by 4point0 Health Ventures and entrepreneur investors, indicating continued investment as MedVital expands its presence across hospitals in India.
The funding will be utilised to support expansion, accelerate product development, and build capabilities across devices, biomaterials and biologics, while strengthening supply chain efficiency and unit economics.
Founded in 2024, MedVital is developing medical technologies in areas including wound care, regenerative aesthetics and chronic skin conditions. Skin and hair conditions, including wounds, ageing and chronic dermatological issues, are linked to gaps in repair and regeneration. The company aims to address these through technologies designed for specific clinical use case scenarios.
MedVital currently operates in advanced wound care through its NoWound portfolio, which includes Negative Pressure Wound Therapy (NPWT) and a chitosan-based liquid bandage designed for hospital settings. The company reports adoption across more than 200 corporate and public healthcare institutions, supported by repeat usage. Adoption of advanced wound care therapies in India remains at an early stage.
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration, using peptide-led signalling and regenerative pathways.
Commenting on the fundraise, Dr. Varun Gupta, Co-Founder, MedVital, said, “Skin, the body’s largest organ, is increasingly impacted by ageing, diabetes and a growing burden of chronic dermatolgical conditions-yet access to innovative, evidence-based technologies remain limited. We’re building clinical driven technologies spanning biomaterials, device based systems, biologics across wound care, aesthetics, and chronic dermatology”.
Alka Goel, Founder and Managing Partner, Alkemi Growth Capital, said, “MedVital is addressing a large and growing clinical need with a platform-led approach. The team has demonstrated early hospital adoption, strong product depth, and disciplined execution, positioning the company to build a globally relevant regenerative care business from India.”
Dr Sanjay Arora, Founding Partner, Shubhan Ventures, added, “The company’s emphasis on product quality, regulatory readiness, and long-term capability building stands out. These are critical foundations for sustainable scale in healthcare.”
MedVital will expand its footprint across hospitals and healthcare institutions while continuing to invest in clinical education and adoption. The company is focused on building a medtech platform based on products and clinical outcomes.